[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_99":100},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","ba6vm0ev5syia61671b1qpvhg","revision",2,"title","GSK plc 股东奖励计划下高管购入普通股","originalTitle","6-K - GSK plc (0001131399) (Filer)","summary","GSK plc 高管在股东奖励计划下购入普通股，每股价格17.5852英镑，涉及人数5人，购入股数从3到80股不等。该交易于2026年10月8日通过伦敦证券交易所完成。","reason","source",{"_11":89,"_90":91,"_92":93,"_94":57,"_95":96,"_97":98},"links",{"_86":87,"_63":88},"publishedAt","2026-10-13T10:27:47.000Z","discoveredAt","2026-10-13T17:48:16.064Z","timelineAt","category","tip","tags",[80,81,82,83,84,85],"stockSymbols",[79],"score",34,"selected",false,"channel","news","story",{"_71":72,"_15":73},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":14,"_68":69,"_70":69},"hasTranslation","bodyLanguage","original","factId","fCpptD7jpCVA",{"_71":72,"_15":73},"reportCount","additionalSourceCount",0,"developmentCount","publicId","284e0d49-0a78-4b26-893d-cf4ef83203b9","GSK高管通过分红再投资购入普通股",{"_71":72,"_15":73},"zh","

\n\nUNITED STATES

\n\nSECURITIES AND EXCHANGE COMMISSION

\n\nWashington, D.C. 20549

\n\nForm 6-K

\n\nREPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR\n15d-16

\n\nUNDER THE SECURITIES EXCHANGE ACT OF 1934

\nFor the\nmonth of October 2026

\nCommission\nFile Number 001-15170

\n\nGSK plc

\n(Translation\nof registrant's name into English)

\n\n79 New Oxford Street, London, WC1A 1DG

\n(Address\nof principal executive office)

\nIndicate\nby check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

\nForm\n20-F . . . .X. . . . Form 40-F . . . . . . . .

\n\nGSK plc (the ‘Company’)

\n\nTransaction notification

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nLuke Miels \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nChief Executive Officer \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n3 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nLynn Baxter \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Europe \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n	\n \n\nInitial notification \n\n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n39 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nJames Ford \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP and Group General Counsel, Legal and Compliance \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n	\n \n\nInitial notification \n\n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n13 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDavid Redfern \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident Corporate Development \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n80 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nRegis Simard \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Global Supply Chain \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n32 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nPhilip Thomson \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Global Affairs \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n52 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n	\n \n\nN/A (single transaction) \n
\n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDeborah Waterhouse \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nCEO, ViiV Healthcare and President, Global Health, GSK \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n	\n \n\nInitial notification \n\n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n66 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nVictoria Whyte \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP & Company Secretary \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n	\n \n\nInitial notification \n\n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n62 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nNeil Falkingham \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPCA of Lynn Baxter (President, Europe) \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n	\n \n\nInitial notification \n\n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on shares held\nthrough the Company’s Share Reward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5852 \n	\n \n\n64 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nVictoria Whyte \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP & Company Secretary \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5904 \n	\n \n\n243 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nIain Whyte \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPCA of Victoria Whyte (SVP & Company Secretary) \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.5904 \n	\n \n\n1,182 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-08 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nMaya Martinez-Davis \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, US \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nAmerican Depositary Shares (‘ADS’) \n\n \n\nISIN: US37733W2044 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of notional ADS within Ms Martinez-Davis’s GSK\nExecutive Supplemental Savings Plan account \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n$47.0200 \n	\n \n\n10.155 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-07 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nNew York Stock Exchange (XNYS) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nLynn Baxter \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Europe \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nJulie Brown \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nChief Financial Officer \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nJames Ford \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP and Group General Counsel, Legal and Compliance \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n\n	\n \n\n2026-10-09 \n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDavid Redfern \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Corporate Development \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nRegis Simard \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Global Supply Chain \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n 14\nOrdinary Shares \n\n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nPhilip Thomson \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident, Global Affairs \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDeborah Waterhouse \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nCEO, ViiV Healthcare and President, Global Health, GSK \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nVictoria Whyte \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP & Company Secretary \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n	\n\n\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nNeil Falkingham \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPCA of Lynn Baxter (President, Europe) \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares under the Company’s Share\nReward Plan \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (partnership shares) \n\n	\n\n
\n\n	\n \n\n£17.6539 \n	\n \n\n7 (matching shares) \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n	\n\n
\n \nAggregated\nvolume \n\n \nPrice \n	\n\n \n\n14 Ordinary Shares \n\n \n\n£17.6539 \n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDavid Redfern \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident Corporate Development \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6650 \n	\n \n\n7 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nNeil Falkingham \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPCA of Lynn Baxter (President, Europe) \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6650 \n	\n \n\n7 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n\n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nDavid Redfern \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nPresident Corporate Development \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on Ordinary Shares\nheld within an ISA \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6650 \n	\n \n\n20 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n\n	\n \n\n2026-10-09 \n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n \n\n1. \n	\n \n\nDetails of PDMR/person closely associated with them\n(‘PCA’) \n\n
\n \na) \n	\n \nName \n	\n \n\nVictoria Whyte \n\n
\n \nb) \n	\n \nPosition/status \n	\n \n\nSVP & Company Secretary \n\n
\n \nc) \n	\n \nInitial\nnotification/amendment \n\n	\n \n\nInitial notification \n
\n \n\n2. \n	\n \n\nDetails of the issuer, emission allowance market participant,\nauction platform, auctioneer or auction monitor \n\n
\n \na) \n	\n \nName \n	\n \n\nGSK plc \n\n
\n \nb) \n	\n \nLEI \n	\n \n\n5493000HZTVUYLO1D793 \n\n
\n \n\n3. \n	\n \n\nDetails of the transaction(s): section to be repeated for (i) each\ntype of instrument; (ii) each type of transaction; (iii) each date;\nand (iv) each place where transaction(s) has been\nconducted \n\n
\n \na) \n	\n \nDescription\nof the financial instrument \n	\n \n\nOrdinary shares of 31 ¼ pence each (‘Ordinary\nShares’) \n\n \n\nISIN: GB00BN7SWP63 \n\n
\n \nb) \n	\n \nNature\nof the transaction \n	\n \n\nAcquisition of Ordinary Shares following the re-investment of\ndividends paid to shareholders on 8 October 2026 on Ordinary Shares\nheld within an ISA \n\n
\n \nc) \n	\n \nPrice(s)\nand volume(s) \n	\n\n	\n \n\nPrice(s) \n	\n \n\nVolume(s) \n\n	\n\n
\n\n	\n \n\n£17.6650 \n	\n \n\n17 \n\n	\n\n
\n\n	\n\n	\n\n	\n\n
\n \nd) \n	\n \nAggregated\ninformation \n\n \nAggregated\nvolume \n\n \nPrice \n\n	\n \n\nN/A (single transaction) \n\n\n
\n \ne) \n	\n \nDate\nof the transaction \n	\n \n\n2026-10-09 \n \n
\n \nf) \n	\n \nPlace\nof the transaction \n\n	\n \n\nLondon Stock Exchange (XLON) \n

\n\nAbout GSK

\n\nGSK is a global biopharma company with a purpose to unite science,\ntechnology, and talent to get ahead of disease together. Find out\nmore at www.gsk.com.

\n\nRegistered in England & Wales:

No.\n3888792

\n\nRegistered Office:

\n\n79 New Oxford Street

\n\nLondon

WC1A\n1DG

\n\nSIGNATURES

\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf\nby the undersigned, thereunto duly authorised.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n \n\nGSK plc \n
\n\n	\n \n(Registrant) \n
\n\n	\n\n
\n \nDate: October\n12, 2026 \n	\n\n
\n\n	\n\n
\n\n	\n \nBy:/s/ VICTORIA\nWHYTE \n \n-------------------------- \n
\n\n	\n\n
\n\n	\n \nVictoria Whyte \n
\n\n	\n \nAuthorised\nSignatory for and on \n
\n\n	\n \nbehalf\nof GSK plc \n

","zhKind","complete","GSK","政策与监管","财报","并购","回购","股息","其他","aihot","/items/ba6vm0ev5syia61671b1qpvhg","https://www.sec.gov/Archives/edgar/data/1131399/000165495426008889/0001654954-26-008889-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]